July 19 - 22, 2019
Hyatt Regency San Francisco
San Francisco, California
Abstract submission deadline: Wednesday, May 1
Advance registration deadline: Friday, June 7
Friday, July 19, 2019
Saturday, July 20, 2019
Sunday, July 21, 2019
Monday, July 22, 2019
Welcome and Opening Keynote Addresses 5-7 p.m.
Next generation CAR T cellsCrystal Mackall, Stanford University, Stanford, California
A path towards successful T cell therapy for solid cancers Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas
Opening Reception7-9 p.m.
Top of pageSaturday, July 20, 2019Breakfast7-8 a.m. Plenary Session 1: Cellular Therapy Clinical Updates (I)8-10 a.m.
Chimeric antigen receptor T cell therapy for chronic lymphocytic leukemiaSaar Gill, University of Pennsylvania, Philadelphia, Pennsylvania
CAR-T antigen evasion: The emerging role for multi-targeted CAR therapyDavid Miklos, Stanford University, Stanford, California
Advancing CAR T cells for the treatment of brain tumorsChristine Brown, City of Hope National Medical Center, Duarte, California
Plenary Session 2: CAR T Cell Engineering – Barriers for Targeting Solid Tumors10:30 a.m.-12:30 p.m.
Engineering lymphocytes for the adoptive immunotherapy of solid tumors Stephen Gottschalk, St. Jude Children’s Research Hospital, Memphis, Tennessee
Molecular and epigenetic programs defining tumor-specific T cell dysfunction and therapeutic reprogrammabilityAndrea Schietinger, Memorial Sloan Kettering Cancer Center, New York, New York
Engineering T cells to eradicate tumors: It starts with the TCR but doesn't stop therePhilip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WashingtonLunch and Poster Session A12:30-2:30 p.m.
Plenary Session 3: Scalability of T Cell Therapy – Driving Down Costs2:30-4 p.m.
Allogene: Leading the next revolution in cell therapyBarbra J. Sasu, Allogene Therapeutics, San Francisco, California
Scalability of T cell therapyGwendolyn Binder-Scholl, Adaptimmune, Philadelphia, Pennsylvania
Innovating and planning our way to improve affordability and accessibility for chimeric antigen receptor (CAR) T cell therapiesHeidi Zhang, Celgene Corp., Seattle, Washington
Plenary Session 4: NK and Other Immune Cell Therapies4:15-6:15 p.m.
Off-the-shelf CAR-engineered cord blood-derived NK cells for the treatment of cancerKaty Rezvani, University of Texas MD Anderson Cancer Center, Houston, Texas
TGFβ-resistant T and NK cells for cancerCatherine Bollard, Children’s National Health System, Washington, D.C.
Selective expansion of adaptive natural killer cells for cancer immunotherapy
Karl Johan Malmberg, The University of Oslo, Oslo, Norway
Top of pageSunday, July 21, 2019Breakfast7:00-8:00 a.m. Plenary Session 5: Cellular Therapy Clinical Updates (II)8-10 a.m.
CAR T-cell therapy for lymphomas: Current and future strategiesSattva Neelapu, The University of Texas MD Anderson Cancer Center, Houston, Texas
Expanding CAR T cell therapy to a wide spectrum of pediatric malignanciesJulie Park, Seattle Children's Hospital, Seattle, Washington
Addressing relapse associated with leukemic resistance to CAR T cellsTerry Fry, University of Colorado Denver and Children's Hospital Colorado, Aurora, Colorado
Plenary Session 6: Optimization of Target Antigens for TCR and TIL10:30 a.m.- 12:30 p.m.
Novel naturally presented targets for personalized T-cell therapiesHarpreet Singh, Immatics US, Inc., Houston, Texas
T cell receptor gene therapy for epithelial cancersChristian Hinrichs, National Cancer Institute, Bethesda, Maryland
Personalized neoantigen-targeting adoptive TCR-T cell therapies for solid tumors Alex Franzusoff, PACT Pharma, Inc., South San Francisco, California
Lunch on Own12:30-2:30 p.m.
Plenary Session 7: Combination Therapy with Adoptive Cell Therapy
Role of marrow infiltrating lymphocytes in adoptive T cell therapyIvan Borrello, Johns Hopkins University, Baltimore, Maryland
Combining checkpoint blockade with CAR T cell therapy to augment response
Shannon Maude, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Reception and Poster Session B4:30-6:30 p.m.
Top of pageMonday, July 22, 2019Breakfast7-8 a.m.
Plenary Session 8: Enhancing Immune Cell Function through Genetic Engineering8-10 a.m.
Tumor infiltrating lymphocyte therapy for metastatic melanomaRodabe Amaria, MD Anderson Cancer Center, Houston, Texas
Enhancing CAR T cell therapy by enabling CAR T cell interaction with antigen-presenting cellsClare Slaney, Peter MacCallum Cancer Center, Melbourne, Australia
Strategies to improve CAR T persistence and solid tumor targetingAvery Posey, Jr., University of Pennsylvania, Philadelphia, Pennsylvania
Plenary Session 9: Novel Approaches for Gene Delivery (Engineered Vectors and Viral Delivery Systems)10:30 a.m.-12:30 p.m.
T cells genetically modified using non-viral gene transfer to target cancer
Laurence Cooper, Ziopharm Oncology, Boston, Massachusetts
Reprogramming human immune cell circuitry
Alexander Marson, University of California San Francisco, San Francisco, California
Engineering smarter and stronger T cells for cancer immunotherapyYvonne Chen, University of California Los Angeles, Los Angeles, California
Closing Remarks 12:30 p.m.
Top of page